IGF1R and neoplasm: For ES however, small molecule inhibitors instead of antibodies may be the drugs of choice since it was recently demonstrated in in vivo ES models that a smaller IGF-1R-targeting compound exerted superior tumor penetrating and thus better IGF-1R-targeting properties than a relatively large IGF-1R-targeting antibody [44].